Maximum Dose of Mounjaro for Weight Loss
The maximum dose of Mounjaro (tirzepatide) for weight loss is 15 mg injected subcutaneously once weekly in adults. 1
Dosing Algorithm
The FDA-approved dosing schedule follows a structured escalation protocol 1:
Starting dose: 2.5 mg once weekly (for treatment initiation only, not for therapeutic effect)
After 4 weeks: Increase to 5 mg once weekly
Subsequent escalation: Increase in 2.5 mg increments after at least 4 weeks on each dose if additional weight loss is needed
Maximum dose: 15 mg once weekly
Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
Clinical Context and Evidence
The 15 mg maximum dose demonstrates the most substantial weight loss effects. According to the 2025 ADA guidelines, tirzepatide at 15 mg weekly produces a mean weight loss of 14.7%, compared to 12.8% at 10 mg and 9.6% with semaglutide 2.4 mg 2. Real-world data confirms these findings, with the 15 mg dose achieving weight reductions where 88.1% of participants lost >5%, 63.3% lost >10%, and 51.8% lost >15% of body weight 3.
Recent 2025 real-world evidence shows that at 1 year, tirzepatide produces mean weight loss of -17.2 kg (-16.5%), though notably only 25.9% of patients reached the maximum 15 mg dose in routine practice 4. This suggests that many patients achieve clinically meaningful weight loss at submaximal doses.
Important Dosing Considerations
Dose escalation is mandatory to reduce gastrointestinal adverse events 1. The gradual titration schedule (increasing every 4 weeks minimum) significantly improves tolerability, as GI side effects are most common during dose escalation 5.
Not all patients require maximum dosing. Real-world studies demonstrate that lower maintenance doses can be effective—one 2026 study found mean doses of 5.32 mg produced 16% weight loss at 24 weeks when combined with lifestyle modification 6, and another showed 2.5 mg versus 5 mg had similar efficacy in Japanese adults (62.1% vs 63.0% achieving primary outcome) 7.
Long-term maintenance matters. The SURMOUNT-MAINTAIN trial demonstrated that continuing tirzepatide at maximum tolerated dose (10 or 15 mg) maintained -21.9% weight loss at 112 weeks, while dose reduction to 5 mg resulted in -16.6% weight loss, and placebo led to significant regain at -9.9% 5. This underscores that ongoing therapy at adequate doses is essential for sustained weight management.
Safety Profile
The most common adverse events are gastrointestinal (nausea, vomiting, diarrhea), typically mild-to-moderate and transient 8. Black box warning: Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 1.
Practical Implementation
Administer once weekly, any time of day, with or without meals, via subcutaneous injection in abdomen, thigh, or upper arm 1. If a dose is missed, administer within 4 days; if >4 days have passed, skip and resume regular schedule 1.
The 2025 BMJ guidelines note that when choosing between GLP-1 receptor agonists and tirzepatide, clinicians should weigh the higher certainty of cardiovascular and kidney benefits (offered by GLP-1 receptor agonists) against larger weight loss benefits (offered by tirzepatide) 9. For patients at higher cardiovascular risk prioritizing tirzepatide, concurrent SGLT-2 inhibitor therapy is indicated 9.